Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improving syndromic testing in oncology: performance characteristics of multiplex PCR assays for evaluation of infectious gastroenteritis among hospitalized cancer patients.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026

Same author

CYTH4 Facilitates Renal Cell Carcinoma via Enhancing Proliferation and Likely Immune Evasion.

Biomolecules·2026

Same author

The Sig27 multigene stratifies breast cancer fatality risk via reflecting tumor-associated immune suppressive features.

Translational oncology·2026

Same author

Clinical cure of chronic hepatitis B is associated with priming and perpetuation of hepatic CD4<sup>+</sup> T cell responses.

Science translational medicine·2026

Same author

PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment.

Journal of advanced research·2026

Same author

Time to change internal medicine training for UK resident doctors.

Lancet (London, England)·2026

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Changes in PKM2 associate with prostate cancer progression.

Nicholas Wong¹, Judy Yan, Diane Ojo

¹Division of Nephrology, Department of Medicine, McMaster University,1.

Cancer Investigation

|June 3, 2014

Summary

Pyruvate kinase M2 (PKM2) is crucial for cancer metabolism. This study found elevated PKM2 levels and specific modifications correlate with advanced prostate cancer (PC) progression and aggressiveness.

Keywords:

Cancer Metabolism PKM2 Prostate cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Experiment Videos

Last Updated: Apr 28, 2026

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Area of Science:

Biochemistry
Oncology
Cancer Metabolism

Background:

Pyruvate kinase M2 (PKM2) plays a key role in aerobic glycolysis, a metabolic pathway vital for cancer cell proliferation.
Understanding the role of PKM2 in prostate cancer (PC) is crucial for developing targeted therapies.

Purpose of the Study:

To investigate the association between PKM2 expression and posttranslational modifications with prostate cancer progression.
To compare PKM2 levels in different Gleason grades and in tumors derived from prostate cancer stem-like cells (PCSCs) versus non-PCSCs.

Main Methods:

Immunohistochemistry was used to analyze PKM2 expression in 29 primary PC tumors and three lymph node metastatic tumors.
PKM2 levels were assessed in xenograft tumors derived from PCSCs and non-PCSCs.
Posttranslational modifications of PKM2 were examined in PCSCs and non-PCSCs.

Main Results:

PKM2 was significantly elevated in Gleason 8-10 PC tumors compared to Gleason 6-7 tumors.
Higher PKM2 levels were observed in aggressive xenograft tumors derived from PCSCs.
While both PCSCs and non-PCSCs expressed comparable PKM2 levels, distinct posttranslational modifications were identified.

Conclusions:

Upregulation of PKM2 is associated with prostate cancer progression and higher Gleason scores.
Specific posttranslational modifications of PKM2 may contribute to PC aggressiveness and the behavior of PCSCs.
Targeting PKM2 and its modifications presents a potential therapeutic strategy for advanced prostate cancer.